Literature DB >> 17267580

Effects of pan- and subtype-selective N-methyl-D-aspartate receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine.

Magali Peeters1, Martin J Gunthorpe, Paul J L M Strijbos, Paul Goldsmith, Neil Upton, Michael F James.   

Abstract

Spreading depression (SD) has long been associated with the underlying pathophysiology of migraine. Evidence that the N-methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R) is implicated in the generation and propagation of SD has itself been available for more than 15 years. However, to date, there are no reports of NMDA-R antagonists being developed for migraine therapy. In this study, an uncompetitive, pan-NMDA-R blocker, memantine, approved for clinical use, and two antagonists with selectivity for NMDA-R containing the NR2B subunit, (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol (CP-101,606) and (+/-)-(R*,S*)-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine propanol (Ro 25-6981), were investigated to assess their protective effects against SD in the rat. Under isoflurane anesthesia, d.c. potential and the related cortical blood flow and partial pressure of O2 (pO2) were recorded simultaneously at separate cortical sites. Drugs (1, 3, and 10 mg/kg i.p.) were given 1 h or 30 min before KCl application to the brain surface. Core temperature and arterial pCO2,pO2, and pH measurements confirmed physiological stability. KCl induced 7.7+/-1.8 (mean+/-S.D.) SD events with d.c. amplitude of 14.9+/-2.8 mV. Memantine and CP-101,606 dose-dependently decreased SD event number (to 2.0+/-1.8 and 2.3+/-2.9, respectively) and SD amplitude at doses relevant for therapeutic use. Ro 25-6981 also decreased SD events significantly, but less effectively (to 4.5+/-1.6), without affecting amplitude. These results indicate that NR2B-containing NMDA receptors are key mediators of SD, and as such, memantine- and NR2B-selective antagonists may be useful new therapeutic agents for the treatment of migraine and other SD-related disorders (e.g., stroke and brain injury). Whether chronic, rather than acute, treatment may improve their efficacy remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17267580     DOI: 10.1124/jpet.106.117101

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  30 in total

1.  The effects of acute and preventive migraine therapies in a mouse model of chronic migraine.

Authors:  Alycia F Tipton; Igal Tarash; Brenna McGuire; Andrew Charles; Amynah A Pradhan
Journal:  Cephalalgia       Date:  2016-07-19       Impact factor: 6.292

2.  Memantine for the prophylaxis of chronic tension-type headache.

Authors:  Katherine A Henry
Journal:  Curr Pain Headache Rep       Date:  2009-12

Review 3.  Chaos and commotion in the wake of cortical spreading depression and spreading depolarizations.

Authors:  Daniela Pietrobon; Michael A Moskowitz
Journal:  Nat Rev Neurosci       Date:  2014-06       Impact factor: 34.870

4.  The neurobiology of migraine.

Authors:  Andrew Charles; K C Brennan
Journal:  Handb Clin Neurol       Date:  2010

Review 5.  Glutamate and Its Receptors as Therapeutic Targets for Migraine.

Authors:  Jan Hoffmann; Andrew Charles
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

6.  Systematic review of the pharmacological agents that have been tested against spreading depolarizations.

Authors:  Anna Klass; Renan Sánchez-Porras; Edgar Santos
Journal:  J Cereb Blood Flow Metab       Date:  2018-04-20       Impact factor: 6.200

Review 7.  Migraine is a neuronal disease.

Authors:  J Tajti; A Párdutz; E Vámos; B Tuka; A Kuris; Zs Bohár; A Fejes; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2010-12-15       Impact factor: 3.575

Review 8.  Cortical spreading depression and migraine.

Authors:  Andrew C Charles; Serapio M Baca
Journal:  Nat Rev Neurol       Date:  2013-09-17       Impact factor: 42.937

9.  Excitatory neurotransmitters in brain regions in interictal migraine patients.

Authors:  Andrew Prescot; Lino Becerra; Gautam Pendse; Shannon Tully; Eric Jensen; Richard Hargreaves; Perry Renshaw; Rami Burstein; David Borsook
Journal:  Mol Pain       Date:  2009-06-30       Impact factor: 3.395

Review 10.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.